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Pioneer work on viral oncoproteins led to the 
discovery in the 1980s of several essential regu-
lators of cell division and cell survival. Among 
those, E4F1 was originally identified as a cellu-
lar target of the E1A viral oncoprotein during 
adenoviral infection and was originally charac-
terized for its implication in the transcriptional 
regulation of the viral E4 promoter (Lee and 
Green, 1987; Lee et al., 1987; Raychaudhuri   
et al., 1987). In addition to its intrinsic tran-
scriptional activities (Fajas et al., 2001; Ahmed-
Choudhury et al., 2005), E4F1 also exhibits an 
atypical ubiquitin E3 ligase function that targets 
other transcription factors, including the p53 
tumor suppressor (Le Cam et al., 2006). Although 
the complex transcriptional program regulated 
by E4F1 remains poorly understood, E4F1 is 
implicated in several steps controlling cell cycle 
progression in both somatic and embryonic 
cells (Fernandes et al., 1998; Rooney, 2001;   
Le Cam et al., 2004). Furthermore, E4F1 was 
recently shown to be essential for epidermal 
stem cell maintenance and proper skin homeosta-
sis in murine epidermis (Lacroix et al., 2010).
Growing evidences suggest that E4F1 is im-
plicated in carcinogenesis. Consistent with that 
notion, E4F1 was found to be regulated by 
and/or to interact with several viral oncopro-
teins, including E1A13S (adenovirus serotype V; 
Raychaudhuri et al., 1987), GAM1 (adenovirus 
Celo; Colombo et al., 2003), and HBX (hepati-
tis virus B; Rui et al., 2006). In addition, E4F1 
is involved in several essential oncogenic path-
ways, including the RB and p53 tumor sup-
pressor  pathways.  Indeed,  inactivation  of  Rb 
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The multifunctional E4F1 protein was originally discovered as a target of the E1A viral 
oncoprotein. Growing evidence indicates that E4F1 is involved in key signaling pathways 
commonly deregulated during cell transformation. In this study, we investigate the influ-
ence of E4F1 on tumorigenesis. Wild-type mice injected with fetal liver cells from mice 
lacking CDKN2A, the gene encoding Ink4a/Arf, developed histiocytic sarcomas (HSs), a 
tumor originating from the monocytic/macrophagic lineage. Cre-mediated deletion of E4F1 
resulted in the death of HS cells and tumor regression in vivo and extended the lifespan of 
recipient animals. In murine and human HS cell lines, E4F1 inactivation resulted in mito-
chondrial defects and increased production of reactive oxygen species (ROS) that triggered 
massive cell death. Notably, these defects of E4F1 depletion were observed in HS cells but 
not healthy primary macrophages. Short hairpin RNA–mediated depletion of E4F1 induced 
mitochondrial defects and ROS-mediated death in several human myeloid leukemia cell 
lines. E4F1 protein is overexpressed in a large subset of human acute myeloid leukemia 
samples. Together, these data reveal a role for E4F1 in the survival of myeloid leukemic 
cells and support the notion that targeting E4F1 activities might have therapeutic interest.
© 2011 Hatchi et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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RESULTS
Development of a mouse histiocytic sarcoma (HS) model 
harboring the E4F1 conditional KO allele
To study E4F1 functions during tumorigenesis, we used a 
recently developed genetically engineered mouse model 
containing  E4F1-null  and  E4F1  conditional  KO  alleles 
(E4F1/flox) based on the Cre/Lox-P technology (Fig. 1 A and 
Fig. S1 A; Le Cam et al., 2004; Lacroix et al., 2010). E4F1/flox 
mice were crossed with RERT mice, a knockin (KI) strain 
expressing the 4-hydroxy-tamoxifen (4OHT)–inducible Cre-
ERT2 fusion protein under the control of the ubiquitously 
active promoter of the RNA polymerase II large subunit gene 
(Guerra et al., 2003). In vivo recombination efficiency of the 
E4F1flox allele was assessed in several organs of E4F1/flox; 
RERTKI/KI mice by quantitative PCR (qPCR) on genomic 
DNA, RT-qPCR on purified RNA, or Western blot analyses 
of total protein extracts (Fig. 1 B and Fig. S1 A). Upon 4OHT 
administration, high recombination efficiency was detected in 
several organs, including liver, spleen, and lungs, as well as in 
peripheral white blood cells and total or purified lineage-
negative (Lin) BM cells (Fig. 1 B). These analyses validated 
our model and confirmed that E4F1 is efficiently deleted 
upon  Cre  activation  in  the  hematopoietic  compartment. 
However, analyses of E4F1/flox; RERTKI/KI mice also revealed 
critical roles of E4F1 in other organs, limiting long-term in-
vestigations of phenotypes resulting from E4F1 loss in the 
hematopoietic compartment in that mouse model.
To address E4F1 functions during tumorigenesis, we next 
crossed E4F1flox; RERTKI/KI animals with Ink4a/Arf KO mice. 
The latter strain of mice harbors a deletion of exons 2 and 3 
of the Ink4a/Arf locus and therefore expresses neither p16INK4a 
nor p19ARF. Ink4a/Arf-null animals are tumor prone and were 
previously described to develop with high penetrance essen-
tially B and T cell lymphomas and soft tissue sarcomas with an 
expected mean age of tumor appearance around 30 wk (Serrano 
et al., 1996). To avoid defects resulting from E4F1 inactivation 
in the whole organism and investigate E4F1 functions during 
tumorigenesis, we transplanted fetal liver hematopoietic stem 
cells (HSCs) isolated from E4F1/flox; RERTKI/KI; Ink4a/Arf/ 
embryos or their control E4F1+/flox; RERTKI/KI; Ink4a/Arf/ 
littermates into lethally irradiated WT recipient mice (herein 
referred to as E4F1 KO or CT; Ink4a/Arf KO mice, accord-
ing to the genotype of the transplanted cells). We used this 
strategy to generate several cohorts of tumor-prone mice in 
which E4F1 could be acutely inactivated specifically in the 
hematopoietic system and in tumors derived from those cells 
upon administration of 4OHT (Fig. S1 B).
We then carefully monitored our transplanted mice for 
perturbations of the hematopoietic system and for tumor sus-
ceptibility. Strikingly, we found that our cohorts of trans-
planted  animals,  regardless  of  E4F1  genotype  and  in  the 
absence of 4OHT administration, developed with full pene-
trance HSs, a tumor type originating from the monocytic/
macrophagic lineage, but no B nor T cell lymphomas. These 
tumors arose as soon as 10 wk after transplantation, and post-
mortem histological analyses indicated that all transplanted 
decreases E4F1 antiproliferative activities (Fajas et al., 2000), 
and E4F1 impinges on the p53 pathway at different levels. 
Thus, through its atypical ubiquitin E3 ligase domain, E4F1 
modulates p53 transcriptional activities independently of 
degradation and modulates its effector functions involved in 
alternative cell fates: growth arrest or apoptosis (Sandy et al., 
2000; Le Cam et al., 2006). E4F1 also directly interacts with 
upstream regulators of the p53 pathway such as the polycomb 
member Bmi1 (Chagraoui et al., 2006), a transcriptional re-
pressor of the CDKN2A locus (also referred to as the Ink4a/
Arf locus), as well as with one of its encoded proteins, the 
p14ARF tumor suppressor (Rizos et al., 2003). Finally, E4F1 
interacts with the p53 target gene product FHL2/Dral that 
modulates E4F1-p53 binding (Paul et al., 2006).
Although they play important roles in E4F1-associated 
activities, genetic evidence indicates that E4F1 functions 
extend beyond the Rb and p53 pathways. Thus, functional 
inactivation of either pathway only partly rescues phenotypes 
associated with E4F1 gain or loss of functions. Consistent 
with that notion, peri-implantation lethality of E4F1 KO 
embryos is not rescued by concomitant inactivation of p53 
(unpublished data), and E4F1 KO epidermal stem cell defects 
are partly but not fully rescued upon genetic inactivation of 
the p53 pathway (Lacroix et al., 2010). Recent data also sug-
gest that E4F1 participates in other oncogenic pathways, as 
shown by its direct interaction with several tumor suppressors 
or  oncogenes,  including  RASSF1A  (Fenton  et  al.,  2004; 
Ahmed-Choudhury et al., 2005), HNF1 (Dudziak et al., 
2008), SMAD4 (Nojima et al., 2010), and HMGA2 (Tessari 
et al., 2003). Thus, those interactions raise the question about 
E4F1 functions that are independent of the Rb and p53 path-
ways, in particular during tumor development.
In this study, we started to address the importance of 
E4F1 during tumorigenesis, using a mouse model harbor-
ing a genetic alteration of the Ink4a/Arf locus. By virtue of 
specific promoters and first exons, this locus generates two 
transcripts with distinct open reading frames encoding the 
p16INK4a  and ARF  proteins  that  exhibit  independent  but 
synergistic tumor suppressor activities through their implica-
tion in the Rb and p53 pathways, respectively (Quelle et al., 
1995; Kamijo et al., 1997; Sharpless et al., 2001; Kim and 
Sharpless,  2006;  Berger  and  Bardeesy,  2007).  Loss  of  the 
Ink4a/Arf  locus  or  functional  inactivation  of  its  encoded 
proteins occurs in a wide spectrum of human tumors, in-
cluding melanoma, pancreatic adenocarcinoma, glioblastoma, 
lung cancer, bladder carcinoma, and lymphoid and myeloid 
leukemias (Kim and Sharpless, 2006). In this study, we ad-
dressed the direct implication of E4F1 in leukemic devel-
opment  in  a  tumor-prone  mouse  model  resulting  from 
Ink4a/Arf inactivation. In that model, as well as in several 
human myeloid leukemia cell lines, E4F1 inactivation re-
sulted in mitochondrial defects and oxidative stress–mediated 
cell death. In addition, we found that E4F1 is overexpressed 
in a large subset of human acute myeloid leukemias (AMLs). 
Altogether, our data show an important function of E4F1 in 
tumor cell survival.JEM Vol. 208, No. 7 
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between 3 and 11 mo after transplantation, according to 
E4F1 status (Fig. 2 A).
Altogether, these data indicated that we established a novel 
murine HS model based on transplantation of Ink4a/Arf-null 
fetal liver HSCs. Tumors that developed in that animal model 
also harbored the E4F1 conditional KO allele, allowing us to 
address the roles of E4F1 during tumor development.
E4F1 inactivation results in decreased tumor development 
and increased life span
Next, we addressed the consequences of E4F1 inactivation in 
transplanted animals. For evaluation of tumor susceptibility, 
recipient mice were transplanted with fetal HSCs harvested 
from genetically matched E4F1+/flox or E4F1/flox; RERTKI/KI; 
Ink4a/Arf+/+ or Ink4a/Arf/ mice (herein referred to as 
E4F1 CT or KO; Ink4a/Arf WT or KO, according to the 
genotype of the transplanted cells). In the first experimental 
group, 4OHT was administered in reconstituted animals 10 wk 
after transplantation to allow full reconstitution of the hema-
topoietic system before Cre-mediated recombination. Adminis-
tration of 4OHT was then repeated on a monthly basis until 
the death of the animals (Fig. S1 B).
animals showed diffuse and/or nodular neoplastic infiltra-
tions in the spleen, liver, or lungs. Pathological analyses of 
tumors recovered from reconstituted animals confirmed that 
they exhibited all phenotypic and immunological features 
reminiscent of human HSs, according to the international 
World Health Organization classification of human tumors. 
HS tumor cells appeared as large cells with abundant eosin-
ophilic cytoplasm and pleiomorphic nuclei with large nu-
cleoli (Fig. 1 C) and showed positive immunoreactivity with 
the histiocytic cell surface markers F4/80 and/or Mac2 and 
heterogenous  staining  for  the  proliferation  marker  Ki67 
(Fig. 1 D and Fig. 2 B). All tumors stained negative for B and 
T cell markers (Fig. S1 D), indicating that none of the trans-
planted animals developed the previously described B or   
T cell lymphoma spectrum found in Ink4a/Arf KO animals 
(Serrano et al., 1996). Increased number of F4/80-positive 
HS cells was also detected by flow cytometry in the periph-
eral blood between 10 and 20 wk after transplantation and 
indicated the progression of the disease (Fig. S1 F). Finally, 
most of these transplanted animals exhibited profound ane-
mia and body weight loss at late stages of tumor progres-
sion (unpublished data). Death of those animals occurred   
Figure 1.  Development of a mouse model of HS harboring the E4F1 conditional KO allele. (A) Schematic representation of the different E4F1flox, 
RERT KI, and Ink4a/Arf-null alleles. (B) RT-qPCR and immunoblot (IB) analyses of E4F1 expression in tissues isolated from E4F1+/flox; RERTKI/KI (CT) or E4F1/flox; 
RERTKI/KI (KO) mice after repeated administration of 4OHT. RT-qPCR products were loaded on agarose gels (top) after real-time PCR amplification to verify 
fragment size and purity of amplicons. HPRT mRNA and GAPDH protein were used to normalize RT-qPCR and immunoblots, respectively. Bar graph shows 
mean ± SD (n = 3) of RT-qPCR data. BM cells represent total BM cells. BM Lin (lineage negative) cells represent a fraction of purified BM cells enriched in 
HSCs and progenitor cells that were negatively selected for expression of lineage-specific markers (CD3, B220, Ter119, Gr-1, and Mac1). **, P < 0.01; ***, P < 
0.001. (C) Microphotographs of representative H&E-stained histological lung and liver sections from transplanted mice. Dashed lines indicate the edge of the 
infiltrating HS. Insets show high-magnification images of HS cells exhibiting large eosinophilic cytoplasm and reniform nucleus. (D) Immunophenotypical 
analysis of HS. Representative tumors observed in the lung and liver were analyzed by IHC using antibodies for the proliferation marker Ki67 (brown staining) 
and the histiocytic marker F4/80 (dark purple staining), as indicated. Insets show high-magnification images of HS cells. Bars, 50 µm.1406 E4F1 drives survival of myeloid leukemic cells | Hatchi et al.
illustrating the normal progression of the disease. In striking 
contrast, we found that E4F1 inactivation, upon 4OHT 
administration to E4F1 KO; Ink4a/Arf KO animals, resulted 
in a strong decrease of PET signal in both the liver and spleen 
(Fig. 3, A and B; and Fig. S2 C). Consistent with this tumor 
regression,  we  observed  on  tissue  sections  prepared  from 
E4F1 KO; Ink4a/Arf KO animals that Mac2-positive HS   
tumor cells exhibited increased TUNEL (terminal deoxynu-
cleotidyl transferase biotin-dUTP nick end labeling) staining, 
which is a hallmark of cell death (Fig. 3 C). Altogether, these 
analyses revealed that E4F1 inactivation delayed HS develop-
ment, increased lifespan in this tumor-prone animal model, 
and induced tumor regression in established HSs.
E4F1 inactivation induced massive cell death of HS cells
Our results prompted us to analyze the cellular consequences of 
E4F1 inactivation in several HS cell lines that we established 
from our HS murine model. Flow cytometry and immuno-
fluorescence analyses indicated that the established cell lines   
expressed predominantly the Mac2 or F4/80 surface markers, 
with some cell lines expressing both markers, confirming their 
histiocytic origin (Fig. S4, A and B). Conditional E4F1 inacti-
vation was induced by the addition of 4OHT in the culture 
medium of E4F1/flox HS cell lines (hereafter referred to as 
E4F1 CT or KO, according to the absence or presence of 
4OHT in the culture medium, respectively), resulting in effi-
cient depletion of the E4F1 protein (Fig. 4 A). E4F1 inactiva-
tion in vitro resulted in a dramatic decrease of viable cells 3 d 
As depicted in Fig. 2 A, E4F1 inactivation significantly 
increased the lifespan of animals transplanted with Ink4a/Arf 
KO cells, with a median survival time (50% survival) of 28 wk 
and 32 wk in E4F1 CT and KO animals, respectively. Of 
note, 20% of E4F1 KO; Ink4a/Arf KO animals exhibited a 
much longer lifespan, with death occurring up to 12 wk later 
than the last E4F1 CT; Ink4a/Arf KO animal. Necropsy and 
histological experiments of all animals, performed at the time of 
their natural death, indicated that loss of E4F1 reduced tumor 
infiltration in the main sites of HS dissemination, including 
lungs, liver, and spleen (Fig. 2 B, Fig. S2 B, and not depicted). This 
reduction of tumor infiltration was also illustrated by a 2.5-fold 
decrease of the median spleen weight (Fig. 2 C) in E4F1 KO; 
Ink4a/Arf KO when compared with control animals.
These pathological analyses suggested that E4F1 inactiva-
tion delayed tumor development in animals transplanted with 
Ink4a/Arf KO cells. To further confirm E4F1 impact on tu-
morigenesis, we set up an independent experimental group 
for longitudinal experiments in which tumor progression was 
monitored on individual animals by in vivo positron emission 
tomography (PET) imaging. We performed quantitative analy-
ses on four independent animals of each genotype (E4F1 
CT or KO; Ink4a/Arf KO). Besides classical PET background 
observed in heart (Fig. S2 A) that precluded analysis of tumor 
development in lungs, we efficiently followed tumor progres-
sion in the liver and spleen. As expected, we observed increased 
PET signal in both the liver and spleen of E4F1 CT; Ink4a/
Arf KO animals during the time course of the experiment, 
Figure 2.  E4F1 inactivation results in 
decreased tumor development and  
increased lifespan. (A) Kaplan-Meier survival 
curve of recipients transplanted with fetal 
liver cells from E4F1+/flox; Ink4a/Arf+/+ (n = 8), 
E4F1/flox; Ink4a/Arf+/+ (n = 16), E4F1+/flox; 
Ink4a/Arf/ (CT; n = 24), and E4F1/flox; 
Ink4a/Arf/ (KO; n = 30) mice, as indicated. 
The arrow indicates the first 4OHT administra-
tion. The dashed lines indicate the median 
survival time (50% lived animals), and the 
double-headed arrow shows the difference in 
that median survival time between the two 
experimental groups: E4F1 WT; Ink4a/Arf KO 
and E4F1 KO; Ink4a/Arf KO. Statistically sig-
nificant differences for pairwise comparison 
were evaluated by a log-rank test. *, P = 0.005. 
(B) IHC analyses of lung sections of E4F1 CT or 
KO mice stained with an antibody for the 
Mac2 histiocytic-specific marker. Representa-
tive microphotographs at low and high mag-
nification are shown. Bars: (left) 1 mm; (right) 
100 µm. (C) Spleen weight of E4F1  
CT or KO animals. A microphotograph of spleen 
from a representative E4F1 CT or KO mouse is 
shown. Untransplanted tumor-free mice (nor-
mal spleen) were used as controls (median ± SD; 
n = 17 for each group; ***, P < 0.001).JEM Vol. 208, No. 7 
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autophagy (unpublished data) 3–4 d after 4OHT treatment, 
just before cell death occurred. Autophagy is a self-degradation 
process implicating the lysosomal pathway in which intracel-
lular membrane structures engulf altered organelles or aggre-
gated proteins. We sought additional experimental evidences 
of autophagy in E4F1 KO HS cells by several complementary 
approaches. Transmission electron microscopy indicated the 
presence of ultrastructural characteristics of autophagic cells, 
such as double-membraned autophagosomes and autolyso-
somes, in E4F1 KO HS cells (Fig. 5 A). Moreover, we ob-
served by immunoblot that E4F1 inactivation resulted in 
the conversion of cytoplasmic LC3 (LC3-I) protein to the 
autophagosome  membrane-bound  form  of  LC3  (LC3-II), 
which is a hallmark of autophagy (Fig. 5 B). Finally, in-
creased formation of autophagosomes and autolysosomes in 
E4F1 KO HSs was visualized by fluorescence microscopy   
after anti-LC3 or acridine orange (AO) stainings, respectively 
(Fig. 5, C and D).
after 4OHT addition. Importantly, E4F1+/flox HS cell lines re-
mained grossly unaffected by 4OHT treatment, confirming 
that the decreased number of viable cells observed in E4F1/flox 
cells was not the consequence of 4OHT toxicity but resulted 
from E4F1 depletion (Fig. 4 A and Fig. S4 C). E4F1 KO HS 
cells exhibited no alteration of their proliferation rate or of their 
mitotic index 4 d after 4OHT addition (Fig. 4 B). However, we 
observed massive cell death upon E4F1 inactivation, as shown 
by increased annexin V staining (Fig. 4 C). Consistent with this 
result, E4F1 inactivation abrogated the formation of colonies in 
anchorage-independent assays (Fig. 4 D). Altogether, these data 
indicated that E4F1 depletion resulted in massive cell death in 
murine HS cell lines established from primary tumors.
E4F1 inactivation results in autophagic cell death  
in HS cells
Time-lapse video microscopy analyses of E4F1 KO HS   
cells showed the apparition of large vacuoles reminiscent of   
Figure 3.  E4F1 inactivation results in cell death and tumor regression in established HSs. (A and B) [18F]FDG-based PET scan analyses were per-
formed on individual E4F1+/flox; RERTKI/KI; Ink4a/Arf/ and E4F1/flox; RERTKI/KI; Ink4a/Arf/ mice before (top) or 2 wk after (bottom) repeated administra-
tions of 4OHT (n = 4 for each group). (A) Representative images showing HSs in the spleen (red dashed lines) and liver (white dashed lines). The color code 
indicates radioactivity intensity (arbitrary units) representing [18F]FDG uptake. Note that strong PET signal in heart and pectoral muscles precluded analy-
sis of tumor progression in the lungs. (B) Quantitative analysis of PET imaging performed on the spleen and liver (fold change representing the ratio be-
tween PET signal after 15 d [D15] and before [D0] 4OHT administration to E4F1 CT or KO mice; median ± SD of four animals for each genotype; *, P < 
0.05). (C) Representative microphotograph of TUNEL staining performed on lung tissue sections prepared from E4F1+/flox; RERTKI/KI; Ink4a/Arf/ (CT) and 
E4F1/flox; RERTKI/KI; Ink4a/Arf/ (KO) mice 15 d after 4OHT administration. Sections were colabeled with TUNEL, Mac2, and DAPI, as indicated. Merge 
images (Mac2, red; TUNEL, green) are shown at higher magnification (boxed areas). Bars, 50 µm.1408 E4F1 drives survival of myeloid leukemic cells | Hatchi et al.
including the transcription factor NRF2, catalase, 
HO1 (heme oxygenase 1), and NQO1 (NAD[P]H 
dehydrogenase quinone 1; Fig. S6, C–F).
Incubation with probes that detect specific ROS 
subtypes such as MitoSOX and OxyBURST confirmed that 
the oxidative stress that resulted from E4F1 inactivation in-
cluded increased levels of superoxide anions of mitochondrial 
origin (Fig. 6 A). These data suggested that this organelle 
could be the main source of ROS detected in E4F1 KO HS 
cells. As a read-out of potential mitochondrial alterations in 
E4F1 KO HS cells, we next determined their in situ oxygen 
consumption rates (OCRs) and ATP levels. Compared with 
control cells, E4F1 KO HS cells exhibited a strong increase in 
O2 consumption (at all levels, i.e., basal respiration, oligomycin 
C–sensitive respiration, and maximum respiratory capacity; 
Fig. 6 B). Strikingly, this strong increase in mitochondrial O2 
consumption was not associated with efficient ATP production 
because E4F1 KO HS cells exhibited decreased ATP levels 
(Fig. 6 C). Because it is well established that various altera-
tions of the electron transport chain functions increase ROS pro-
duction (Koopman et al., 2010), this strongly suggests that E4F1 
KO HS cells display mitochondrial alterations that impinge on 
the efficient coupling between oxygen consumption and ATP 
production, ending in increased ROS production.
The direct consequence of a massive increase in ROS 
levels is the oxidation of the cellular components, including 
DNA. Accordingly, we detected increased levels of 8-hydroxy-
2-deoxyguanosine (8-OHdG) in E4F1 KO HS cells, which 
is a stable marker of oxidatively damaged DNA, as shown by 
nuclear relocalization and increased intensity of the 8-OHdG 
staining (Fig. 6 D; Struthers et al., 1998).
These  data  led  us  to  further  investigate  whether  these 
ROS were the main cause of death that resulted from E4F1 
inactivation. Treatment of E4F1 KO HS cells with the super-
oxide anion scavenger Tiron (4,5-dihydroxy-1,3-benzene di-
sulfonic acid-disodium salt) (a) resulted in reduction of the 
conversion of LC3-I to LC3-II (Fig. 6 E), (b) diminished   
To determine whether induction of autophagy was the 
main cause of E4F1 KO HS cell death, cells were treated with 
the autophagy inhibitor 3-methyladenine (3MA), which blocks 
an early step controlling autophagosome formation (Levine 
and Kroemer, 2008; Mizushima, 2009). 3MA efficiently blocked 
autophagy and cell death in E4F1 KO cells, as shown by de-
creased LC3-II expression and reduced number of annexin V–
positive cells (Fig. 5, B and E). We also evaluated whether 
apoptosis contributed to cell death occurring upon E4F1 inacti-
vation. The z-VAD caspase inhibitor had a minor but signifi-
cant effect on cell death of E4F1 KO HS cells (Fig. S5 A). 
Altogether, these results showed that E4F1 KO HS cells died 
mainly through autophagic cell death with a minor implication 
of apoptosis.
Autophagic cell death of E4F1 KO HS cells results  
from mitochondrial defects and increased reactive  
oxygen species (ROS) levels
Oxidative stress is a well-known inducer of autophagy in a 
variety of cell types including macrophages (Xu et al., 2006). 
Therefore, we wondered whether autophagy observed in 
E4F1 KO HS cells resulted from increased ROS levels. 
E4F1  KO  HS  cells  exhibited  increased  staining  with  the 
2,7-dichlorofluorescein  diacetate  (DCFDA)  probe,  a  cell-
permeable fluorescent dye that reacts with a broad spectrum 
of ROS (Fig. 6 A). Importantly, DCFDA staining in E4F1 
KO HSs was not modified by the autophagy inhibitor 3MA, 
indicating that increased ROS levels resulting from E4F1 in-
activation were not a consequence of autophagic cell death 
(Fig. S6 A). Consistent with the development of an early and 
massive oxidative stress in these cells, a robust antioxidant re-
sponse was detectable early after E4F1 inactivation, as illustrated 
by an increased expression of several antioxidants factors,   
Figure 4.  E4F1 inactivation induces massive cell death 
of HS cells. E4F1/flox; RERTKI/KI; Ink4a/Arf/ HS cells were 
cultured in the presence (KO) or absence (CT) of 4OHT. (A) 3 d 
after vehicle or 4OHT addition in the culture medium, HS 
cells were analyzed by immunoblot and counted (mean ± SD; 
n = 6; ***, P < 0.001). GAPDH was used as a loading control. 
(B) Proliferation rate and mitotic index upon E4F1 inactiva-
tion in HS cells. The percentage of EdU (left)- or phospho–
histone H3 (S10; PHH3; right)–positive cells was evaluated 
by flow cytometry. Nocodazole treatment (Noco) of E4F1 CT 
HS cells was used as a control for PHH3 staining. Bar graphs 
represent the mean ± SD (n = 3). (C) Representative micro-
photographs (top) of E4F1 CT and KO HS cells 4 d after 4OHT 
addition. Flow cytometry analyses (bottom) of annexin V–
positive cells in E4F1 CT and KO HS cells (numbers indicate 
the mean ± SD of n = 7; P < 0.001). Bar, 5 µm. (D) 105 E4F1 
CT and KO HS cells were seeded in soft agar. Bar graph shows 
quantitative evaluation of the total number of colonies formed 
after 3 wk of culture (mean ± SD; n = 3; ***, P < 0.001).JEM Vol. 208, No. 7 
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Increased ROS levels and cell death  
do not occur in E4F1 KO primary  
normal macrophages
Careful monitoring of E4F1 KO or CT; 
Ink4a/Arf WT animals indicated that E4F1 
depletion  did  not  dramatically  affect  the 
different  lymphoid  and  myeloid  popula-
tions in the peripheral blood (not depicted) 
and did not alter the lifespan of those ani-
mals over a 12-mo observation period in 
that experimental setting (Fig. 2 A). There-
fore, we investigated whether cell death re-
sulting from E4F1 inactivation in HS cells 
was specific of transformed cells. To address 
this question, we inactivated E4F1 ex vivo in purified in-
traperitoneal primary murine macrophages. Although effi-
cient E4F1 depletion was obtained upon 4OHT addition 
ex vivo, neither increased oxygen consumption, increased 
ROS levels, nor induced cell death were detected in these 
cells (Fig. 8). These data showed that E4F1 inactivation re-
sulted in cell death selectively in transformed cells originat-
ing from the monocytic/macrophagic lineage but not in 
normal primary macrophages.
E4F1 depletion results in mitochondrial defects, increased 
ROS levels, and cell death in human myeloid tumor cells
The  consequences  of  E4F1  depletion  in  HS  cell  survival 
prompted us to evaluate whether the observed defects could 
be extended to human leukemic cell lines of myeloid origin. 
We first evaluated the consequences of E4F1 depletion in 
nuclear labeling of 8-OHdG (Fig. 6 D), (c) and led to a marked 
decrease in the number of annexin  V–positive cells (Fig. S5 B). 
Similar results were obtained with 3H-1,2 dithiole-3-thione 
(D3T), a chemical compound which increases cellular anti-
oxidant defenses by increasing NRF2 activities (Fig. 6 E and 
Figs. S5 B and S6 H; Zhu et al., 2006). In addition, treatment 
of E4F1 KO HS cells in culture with the ROS scavenger 
N-acetyl-l-cysteine (NAC) rescued cellular viability 3 d after 
4OHT addition (Fig. 7 A). Finally, NAC treatment of E4F1 KO; 
Ink4a/Arf KO animals strongly altered the massive cell death 
occurring in established HSs upon E4F1 inactivation in vivo, 
as shown by decreased TUNEL staining performed on tissue 
sections prepared from these animals (Fig. 7, B and C). Collec-
tively, our data support the notion that E4F1 inactivation in 
HS cells results in mitochondrial defects and oxidative stress 
that lead to autophagic cell death, both in vitro and in vivo.
Figure 5.  E4F1 inactivation in HS cells results 
in autophagic cell death. E4F1/flox; RERTKI/KI; Ink4a/
Arf/ HS cells were cultured in the presence (KO) or 
absence (CT) of 4OHT. (A) Representative microphoto-
graphs of electron microscopy analyses showing the 
formation of autophagic vacuoles in E4F1 KO HS cells 
(top). Higher magnification (bottom) of the same cells 
(boxed areas) showing the apparition of double-
membraned cytoplasmic vacuoles containing dark 
degradation products in E4F1 KO HS cells (white ar-
rows). (B) Quantitative immunoblot analyses of con-
version of LC3-I to LC3-II upon E4F1 inactivation in 
HS cells. Treatment with the autophagy inhibitor 3MA 
is indicated. Actin was used as a loading control. Top 
panels show representative immunoblots. The bottom 
panel represents the quantitative analyses of LC3-II 
levels normalized to actin levels (mean ± SD; n = 3;  
*, P < 0.05; **, P < 0.01; ***, P < 0.001). (C) Represen-
tative microphotograph of HS cells stained with anti-
LC3 antibody and DAPI and visualized by fluorescence 
microscopy. (D) Formation of acidic vesicular organ-
elles in HS cells was visualized by fluorescence mi-
croscopy after staining with the lysosomal-specific 
dye AO and DAPI. (E) Percentage of annexin V–positive 
HS cells was measured by flow cytometry (mean ± SD; 
n = 3). Cells were treated with 3MA where indicated. 
Bars: (A) 500 nm; (C and D) 10 µm.1410 E4F1 drives survival of myeloid leukemic cells | Hatchi et al.
E4F1 is overexpressed in a large subset  
of primary human AML samples
HS is a rare human tumor precluding the analy-
sis of a significant number of samples. Because 
we found that E4F1 depletion induced compa-
rable defects in several leukemic cell lines of myeloid origin, we 
evaluated E4F1 expression levels in AML, a more common 
myeloid malignancy. E4F1 protein level was assessed by quan-
titative immunoblotting on protein extracts prepared from 39 
BM biopsies harvested from patients diagnosed with AML. 
Normal BM samples were used as controls. The vast majority 
(35/39) of AML expressed E4F1 at higher levels than controls, 
with a subgroup (9/39) that we defined as strong overexpres-
sors (4–13-fold increase above controls; Fig. 9 E and Fig. S8 C). 
These data were consistent with our observation that murine 
HS cell lines exhibit a higher amount of E4F1 messenger RNA 
(mRNA) and protein levels compared with primary macro-
phages (Fig. S8, A and B). Thus, this pilot experiment suggested 
that leukemic cells overexpress E4F1 protein, which is consis-
tent with the notion that E4F1 is essential for their survival.
DISCUSSION
Although the multifunctional E4F1 protein is involved in 
essential oncogenic pathways, its exact functions during 
transformation remain poorly understood. In this study, we 
U937 cells, a cell line originally isolated from pleural effusion 
of a patient with HSs (Sundström and Nilsson, 1976). E4F1 
depletion was achieved by transduction of cells with lentivi-
ruses encoding two independent short hairpin RNAs (shRNAs) 
directed against human E4F1 or a control irrelevant shRNA 
(Fig. 9 A). E4F1 depletion in U937 cells resulted in increased 
ROS levels. Comparable results were obtained in other leuke-
mic cell lines, including the acute promyelocytic leukemia 
HL60, the acute monocytic leukemia THP1, and the erythro-
leukemic HEL cell lines (Fig. 9 B and Fig. S8 D). Interestingly, 
similar to murine HS cells, E4F1 depletion in HEL and HL60 
cells resulted in increased oxygen consumption (Fig. 9 C). 
These defects led to massive cell death, as shown by increased 
annexin V staining (Fig. 9 D).
Altogether,  our  data  suggest  that  the  essential  roles  of 
E4F1 in mitochondrial functions and cell survival observed in 
murine HS cells extend to human leukemic cell lines. Based 
on this conclusion, we next conducted a pilot experiment 
aimed at evaluating E4F1 expression levels in samples isolated 
from leukemic patients.
Figure 6.  E4F1 inactivation results in mitochon-
drial defects and increased ROS levels. E4F1/flox; 
RERTKI/KI; Ink4a/Arf/ HS cells were cultured in the pres-
ence (KO) or absence (CT) of 4OHT. (A) Flow cytometry 
analyses of ROS levels measured by DCFDA, OxyBURST, 
and the mitochondria-specific MitoSOX probes in E4F1 
CT and KO HS cells, as indicated. Bar graph represents 
quantitative data showing fold increase of time- 
dependent changes in mean fluorescence intensity of 
MitoSOX measured by flow cytometry (mean ± SD; n = 3; 
***, P < 0.001). (B) Mitochondrial OCR corresponding to 
basal respiration, oligomycin-sensitive OCR, and maximal 
respiration (evaluated upon injection with the uncoupling 
agent FCCP followed by the inhibitor of the mitochon-
drial complex I rotenone) in HS cells, as indicated. Values 
were normalized to total protein levels. Vertical bars indi-
cate the time of injection of the indicated compound. 
Data are represented as the mean ± SD of triplicate ex-
periments. (C) Total ATP levels in E4F1 CT and KO HS cells 
were measured 3 d after 4OHT addition (mean ± SD;  
n = 3; **, P < 0.01). (D) Genomic DNA oxidation was mea-
sured in HS cells by fluorescent microscopy using a direct 
binding assay based on avidin-conjugated FITC that binds 
8-OHdG, in the presence or absence of the superoxide 
anion scavenger Tiron. Representative images of three 
independent experiments are shown. Bars, 10 µm.  
(E) Quantitative immunoblot analyses of LC3 expression 
in total protein extracts prepared from E4F1 CT and KO 
HS cells treated with vehicle, Tiron, or D3T, an inducer of 
cellular antioxidant defenses, as indicated. LC3-II levels 
were normalized to actin levels (mean ± SD; n = 3;  
*, P < 0.05; ***, P < 0.001).JEM Vol. 208, No. 7 
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misclassified and are now recognized 
as diffuse large B cell lymphomas with 
associated reactive macrophages. How-
ever, extensive morphological and im-
munophenotypical analyses confirmed 
that the hematopoietic tumors arising 
in our model are bona fide HSs, ac-
cording  to  criteria  published  in  the 
World Health Organization classifica-
tion of human tumors. The high pen-
etrance of this tumor type raised the 
question about the molecular etiology 
and cell of origin of HSs. Consistent 
with previous studies, our data support 
the cooperating role of functional alter-
ations  of  the  Ink4a/Arf  locus  and   
the phosphoinositide 3-kinase (PI3K) 
pathway in HS pathogenesis in murine models (Eischen et al., 
2002; Lund et al., 2002; Carrasco et al., 2006). Indeed, although 
PTEN protein remained expressed in all HS cell lines estab-
lished from our murine model, we found clear evidence for a 
deregulation of the PI3K pathway, as illustrated by a marked in-
crease in the activating phosphorylation of AKT on Ser473   
(Fig. S3). Because only few relevant HS mouse models exist so 
far (Martín-Caballero et al., 2001; Eischen et al., 2002; Carrasco 
et al., 2006; Khoo et al., 2007), the characterization of this new 
model exhibiting full penetrance and apparent specificity for the 
development of HS might help to better understand the etiol-
ogy of this aggressive disease.
Using  this  tumor-prone  mouse  model,  we  found  that 
E4F1 inactivation resulted in the massive cell death of trans-
formed cells, tumor regression, and increased life span of the 
transplanted animals. Nevertheless, E4F1 KO; Ink4a/Arf KO 
animals still died earlier than E4F1 KO; Ink4a/Arf WT mice. 
evaluated  E4F1  functions  in  tumor  development  in  vivo,   
using an original mouse model based on mice transplanted 
with genetically engineered HSCs harboring Ink4a/Arf-null 
and E4F1 conditional KO alleles. This strategy resulted in the 
generation of a tumor-prone mouse model with unexpected 
tumor spectrum. Although other murine models based on the 
Ink4a/Arf KO allele have previously been shown to develop 
mainly lymphomas and sarcomas (Serrano et al., 1996), we 
failed to detect any pathological evidences of lymphoma de-
velopment in our transplanted mice. The absence of lym-
phoma in our experimental model did not reflect differences 
in genetic backgrounds because genetically matched donor 
mice  developed  lymphomas  with  the  expected  frequency 
(Fig. S1 E). Strikingly, all of our transplanted mice devel-
oped HSs, a rare neoplasm of the histiocytic lineage with 
poor prognosis and aggressive clinical course in humans. 
Most human HS cases previously described were originally   
Figure 7.  ROS scavengers rescue cell 
death occurring in E4F1 KO HS cells.  
(A) E4F1/flox; RERTKI/KI; Ink4a/Arf/ HS cells 
were cultured in the presence (KO) or absence 
(CT) of 4OHT. Number of viable cells assessed 
in the absence or presence of the ROS scaven-
gers Tiron or NAC or upon the addition of D3T 
in E4F1 KO or CT HS cells, as indicated. Bar 
graph represents quantitative analysis show-
ing fold increase of viable HS cells between 
days 0 (DO) and 3 (D3) after 4OHT treatment 
(mean ± SD; n = 3; *, P < 0.05; **, P < 0.01;  
***, P < 0.001). (B and C) Representative mi-
crophotographs of TUNEL staining performed 
on liver tissue sections prepared from vehicle 
(B)- or NAC (C)-treated E4F1+/flox; RERTKI/KI; 
Ink4a/Arf/ (CT) or E4F1/flox; RERTKI/KI; Ink4a/
Arf/ (KO) mice 15 d after 4OHT administra-
tion. Sections were colabeled with TUNEL, 
Mac2, and DAPI as indicated. Merge images 
(Mac2, red; TUNEL, green) are shown at higher 
magnification (boxed areas). Bars, 50 µm.1412 E4F1 drives survival of myeloid leukemic cells | Hatchi et al.
cellular  constituents,  including  pro-
teins,  DNA,  and  lipids. Accordingly, 
we observed that E4F1 inactivation in HS cells associated 
with massive genomic DNA oxidation that was largely abro-
gated upon treatment with ROS scavengers. Furthermore, 
administration of NAC to E4F1 KO Ink4a/Arf KO animals 
prevented the massive cell death that was observed in vivo 
upon E4F1 inactivation in established HSs. Preliminary analyses 
performed by PET scan on a limited number of NAC-treated 
animals also suggested that ROS scavengers prevented tumor 
regression induced by E4F1 inactivation (unpublished data).
Those results raised the question about the source of ROS 
production in E4F1 KO HS cells. Because E4F1 has been 
described as an interactor and a regulator of the tumor sup-
pressor p53 (Le Cam et al., 2006), one possibility was that 
E4F1 depletion had modified some p53 functions leading to 
increased ROS levels and/or activation of an autophagic re-
sponse. Indeed, beside its well documented functions on cell 
cycle and apoptosis, p53 has been recently shown to directly 
modulate DRAM (damage-regulated autophagy modulator), 
a component of the autophagic machinery (Crighton et al., 
2006). Furthermore, transcriptional independent activities of 
cytoplasmic p53 have also been proposed to regulate autoph-
agy (Tasdemir et al., 2008). Finally, p53 has been described to 
mediate pro- as well as antioxidant effects, likely depending 
on the intensity of the p53 response. Paradoxically, both have 
been suggested to participate in its tumor suppressor func-
tions (Vousden and Ryan, 2009). We currently do not favor 
the hypothesis that activation of p53 is involved in increased 
ROS levels found in E4F1 KO HS cells because those cells 
already harbor an altered p53 pathway resulting from genetic 
inactivation of the Ink4a/Arf locus. In addition, shRNA-
mediated depletion of endogenous p53 failed to modulate 
The cause of death of these animals remains unclear. Our data 
do not support the idea that E4F1 inactivation induced severe 
hematopoietic  defects  compromising  the  lifespan  of  those 
transplanted animals. Detailed necropsy analyses performed 
with trained pathologists indicated that some but not all E4F1 
KO; Ink4a/Arf KO animals exhibited lesions that could re-
flect massive and rapid cell death of tumor cells in essential 
organs such as lungs and liver. These defects may have resulted 
in a severe tissue disorganization and animal death.
To decipher E4F1 functions in HS cell survival, we next 
performed extensive analyses in established HS cell lines de-
rived from our animal models. Our previous study indicated 
that E4F1 KO embryos display mitotic progression defects 
followed by cell death at the peri-implantation stage, as illus-
trated by increased mitotic index and aberrant mitotic figures 
(Le Cam et al., 2004). Such defects were not observed in HS 
cells upon acute inactivation of E4F1, suggesting that E4F1 
has different functions in various cell types.
Compelling evidence indicates that E4F1 inactivation in 
HS cell lines turned on a switch toward autophagic cell death, 
a process which likely reflects the well documented propen-
sity of cells originating from the macrophage lineage to 
undergo autophagy in stress conditions (Xu et al., 2006; Huang 
et al., 2009). Seeking the stress that had initiated this response, 
we found that acute E4F1 inactivation in HS cells led to 
mitochondrial defects and increased ROS levels. Importantly, 
rescue experiments based on ROS scavengers or chemical 
compounds that increase cellular antioxidant defenses indi-
cated that these ROS preceded the autophagic cell death re-
sponse in E4F1 KO HS cells. Increased ROS levels observed 
in these cells likely resulted in deleterious oxidation of many 
Figure 8.  E4F1 inactivation does not 
result in mitochondrial defects, increased 
ROS levels, or increased cell death in nor-
mal primary macrophages. Primary macro-
phages were purified from the intraperitoneal 
cavity of age-matched E4F1+/flox; RERTKI/KI or 
E4F1/flox; RERTKI/KI animals. E4F1 inactivation 
was induced ex vivo by the addition of 4OHT 
in the culture medium. Analyses were per-
formed between 4 and 5 d after 4OHT addi-
tion. (A) Immunoblot analysis of E4F1 
expression in E4F1+/flox or E4F1/flox primary 
macrophages. GAPDH was used as a loading 
control. (B) Flow cytometry analysis of intra-
cellular ROS levels (DCFDA) in E4F1 E4F1+/flox 
or E4F1/flox primary macrophages. (C) Primary 
macrophages were stained with annexin V 
and analyzed by flow cytometry. (D) OCRs of 
E4F1+/flox or E4F1/flox primary macrophages 
were measured as described in Fig. 6. Vertical 
bars indicate the time of injection of the indi-
cated compound. Data are represented as the 
mean ± SD of triplicate experiments.JEM Vol. 208, No. 7 
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of events, suggest-
ing  that  the  role   
of  E4F1  in  those   
processes is conserved in murine and human leukemic cells.
The role of ROS in tumorigenesis remains controversial. 
On one hand, many studies describe ROS as inducers of tu-
morigenesis (Klaunig et al., 2010; Ziech et al., 2011). On the 
other hand, previous data have also shown that some cancer 
cells, including leukemic cells, are more sensitive to increased 
ROS levels than their nontransformed counterparts, opening 
a window of opportunity for pro-oxidant anticancer treat-
ments (Huang et al., 2000; Trachootham et al., 2006, 2008; 
Valko et al., 2007). Our data are consistent with the latter 
strategy because we found that E4F1 inactivation induces 
ROS-mediated cell death in HS transformed cells but not in 
normal  primary  macrophages. The  molecular  mechanisms 
that are responsible for the higher sensitivity of cancer cells to 
increased ROS levels still remain unclear. Several explanations 
have been proposed, implicating the lower antioxidant de-
fenses in some tumor cells or the paradoxical role of AKT in 
sensitizing cancer cells to ROS-induced cell death (Huang   
et al., 2000; Nogueira et al., 2008). Based on our data showing 
that transformed but not normal cells display mitochondrial 
increased ROS levels or cell death in E4F1 KO HS cells 
(Fig. S7). Our data rather point to a more direct role of 
E4F1 in the regulation of mitochondrial activities that im-
pinge on ROS levels. Indeed, increased ROS levels were de-
tected by several ROS-sensitive fluorescent probes, including 
dyes that detect superoxide anions of mitochondrial origin. 
Our data support the importance of superoxide anions as   
a byproduct of mitochondrial defects in the induction of 
cell death observed in E4F1 KO HS cells. Consistent with 
that notion, we found that E4F1 inactivation resulted in 
perturbed  mitochondrial  oxygen  consumption  and  de-
creased ATP production, and cell death was partly rescued 
upon treatment with Tiron, which allows detoxification of 
superoxide anions into less toxic ROS. This is of particular 
interest  in  light  of  our  recent  data  showing  that  E4F1  
inactivation in murine fibroblasts perturbed expression of 
several mitochondrial components involved in energetic and 
metabolic processes (unpublished data). These data support 
the notion that high ROS levels in E4F1 KO cells are the   
direct consequence of mitochondrial dysfunctions, which in 
turn induce cell death in HS cells. Furthermore, shRNA- 
mediated depletion of E4F1 in several human transformed 
cell lines of myeloid origin resulted in the same sequence   
Figure 9.  E4F1 is overexpressed in  
human AML samples, and its depletion 
induces mitochondrial defects, increased 
ROS levels, and cell death in human  
myeloid leukemic cell lines. (A) Immunoblot 
analysis of E4F1 expression in human HS 
U937, erythroleukemic HEL, promyelocytic 
leukemia HL60, and acute monocytic leukemia 
THP1 cell lines transduced with lentiviruses 
encoding two independent shRNAs (#1 and 
#2) directed against human E4F1 or a control 
irrelevant shRNA (Ct). (B) Representative flow 
cytometry analyses of ROS levels (DFCDA) in 
U937, HEL, HL60, and THP1 cell lines treated 
with Ct or E4F1 shRNA. (C) O2 consumption in 
human HEL and HL60 myeloid leukemic cell 
lines upon treatment with Ct or E4F1 shRNA, 
as indicated. O2 consumption was measured 
using a Clark-type O2 electrode chamber. Bar 
graph represents the mean ± SD (n = 3;  
*, P < 0.05; ***, P < 0.001). (D) Flow cytometry 
analyses of annexin V–positive cells in human 
myeloid leukemic cell lines treated with Ct or 
E4F1 shRNAs (#1 and #2), as indicated. Bar 
graph represents the mean ± SD (n = 3;  
*, P < 0.05; ***, P < 0.001). (E) E4F1 and actin 
(loading control) protein expression levels 
were evaluated by quantitative immunoblot-
ting on total protein extracts prepared from 
BM samples from adult AML patients. Bar 
graph represents the ratio between E4F1 and 
actin protein levels of individual patients. The 
dotted line represents the mean value of this 
ratio obtained with three normal BM samples. 
The percentage of myeloid leukemic blasts in 
each sample was evaluated to avoid potential 
bias based on heterogeneity of the AML BM 
samples tested.1414 E4F1 drives survival of myeloid leukemic cells | Hatchi et al.
PE-Mac2 for myeloid cells. PE-CD45.1 (Ly5.1) and FITC-CD45.2 (Ly5.2) 
antibodies were used to determine the level of reconstitution by identifying 
the proportion of donor cells in recipient mice. Fluorochrome-conjugated 
antibodies used for flow cytometry analyses (FACSCalibur flow cytometer; 
BD) were purchased from BD and eBioscience. Flow cytometry data were 
analyzed with FlowJo software (Tree Star).
RT-qPCR. E4F1 mRNA expression was evaluated in different hemato-
poietic compartments by RT-PCR. Cells were lysed in TRIZOL reagent 
(Invitrogen), and total RNAs were isolated according to the manufacturer’s 
recommendations. cDNAs were synthesized from 1 µg of total RNA using 
random hexamers and SuperScript III Reverse transcription (Invitrogen). 
Real-time qPCR was performed on a LightCycler 480 SW 1.5 apparatus 
(Roche) with Platinum Taq DNA polymerase (Invitrogen) and an SYBR 
Green mix containing 3 mM MgCl2 and dNTPs 30 µM each; 45 cycles 
of 95°C for 4 s, 62°C for 10 s, and 72°C for 30 s. Results were quanti-
fied with a standard curve generated with serial dilutions of a reference 
cDNA preparation. PCR products were always loaded on an agarose gel 
to verify fragment size and purity of amplicons. RPL13A and HPRT tran-
scripts were used for normalization. Primers sequences were as follows: E4F1 
forward, 5-CCAAAGCCTACCTGCTCAAG-3; and reverse, 5-CTGG-
GCATTCTTGGTTTTGT-3; RPL13A forward, 5-GAGGTCGGGTG-
GAAGTACCA-3;  and  reverse,  5-TGCATCTTGGCCTTTTCCTT-3; 
and HPRT forward, 5-AAGCCTAAGATGAGCGCAAG-3; and reverse, 
5-TTACTAGGCAGATGGCCACA-3.
Histology and immunohistochemistry (IHC). Formalin-fixed tissues 
were embedded in paraffin, sectioned, and processed for routine hematoxylin 
and eosin (H&E) staining and IHC. Anti-Ki67 (SP6) and -MPO (Ab-1) anti-
bodies were obtained from Thermo Fisher Scientific. Anti–CD3- (M-20) 
and -Pax5 (C-20) antibodies were obtained from Santa Cruz Biotechnology, 
Inc., and anti-F4/80 (BM8) and -Mac2 (M3/38) antibodies were obtained 
from eBioscience. IHC was performed on 4-µm tissue sections using the ap-
propriate primary antibodies and the corresponding biotinylated secondary 
antibody coupled to streptavidin–peroxidase complex (ABC Vectastain kit; 
Vector Laboratories). Revelation was performed using the peroxidase sub-
strates DAB (3,3-diaminobenzidine; brown coloration) or VIP (dark purple 
coloration)  from Vector  Laboratories.  TUNEL  staining  was  performed   
according to the manufacturer’s (Roche) instructions.
PET scan analyses. PET scan analyses were performed at the Animage   
imaging department in Lyon (Centre d’Exploration et de Recherche Multi-
modal  et  Pluridisciplinaire,  France).  Animals  analyzed  by  PET  imaging 
belong to an experimental group composed of transplanted animals (4 mo 
after transplantation) that displayed palpable tumors in the spleen and a high 
percentage of F4/80-positive HS cells in the peripheral blood. Quantitative 
PET analyses of four independent animals of each genotype were performed 
on spleen and liver before (day 0) and after (day 15) E4F1 inactivation. Clini-
cal grade radiolabeled fluorodeoxyglucose ([18F]FDG) was produced locally 
using a cyclotron. [18F]FDG uptake was calculated from a whole body acquisition 
of 30-min length on anesthetized animals performed with a high-resolution 
small animal PET scanner (Raytest ClearPET; Crystal Clear Collaboration) 
after i.v. injection of 300 µCi [18F]FDG in 100 µl of 0.9% NaCl solution in 
tail vein. Acquisition started 2 h after [18F]FDG injection to reduce tracer 
uptake in the bladder caused by renal excretion. PET scan images were re-
constructed and quantified according to the injected amounts of [18F]FDG 
using the freeware Amide.
Reagents. AO, 3MA, 4OHT, DAPI, propidium iodide (PI), Tiron, collagenase, 
Hepes, Na pyruvate, Tween 20, and NAC were purchased from Sigma-Aldrich. 
D3T was purchased from Axxora Platform, and Click-it EdU flow cytometry 
assay kit, CM-H2DCFDA, MitoSOX, OxyBURST, and FITC-conjugated avi-
din were purchased from Invitrogen. Annexin  V–FLUOS (herein referred to as 
annexin  V) and BSA were purchased from Roche. RPMI Glutamax-I and FBS 
were purchased from Invitrogen and Biowest, respectively. For experiments on 
defects upon E4F1 depletion, we also do not exclude the pos-
sibility that transformed cells exhibit deregulation of some yet 
unidentified mitochondrial activities that sensitize cancer cells to 
E4F1 depletion. Together with our finding that overexpres-
sion of E4F1 protein level, ranging from moderate (two- to 
fourfold) to high (4–13-fold), occurs in a large subset of AML 
samples, these observations raise an interesting hypothesis that 
some leukemic cells become addicted to the prosurvival func-
tions of E4F1 during the process of cell transformation. In 
conclusion, our findings may have important implications for 
novel anticancer therapies, in particular for treatment of leu-
kemias that have been shown to respond to chemotherapeu-
tic agents that regulate the redox status.
MATERIALS AND METHODS
Generation of mutant mice and E4F1 inactivation in vivo. E4F1-
null and E4F1flox mice were generated previously (Le Cam et al., 2004; 
Lacroix et al., 2010). Ink4a/Arf (Serrano et al., 1996) and RERT (Guerra 
et al., 2003) mice were provided by M. Serrano and M. Barbacid (Centro 
Nacional  de  Investigaciones  Oncológicas,  Madrid,  Spain),  respectively. 
E4F1-null, E4F1flox, RERT, and Ink4a/Arf mice were intercrossed to ob-
tain appropriate genotypes: E4F1+/flox or E4F1/flox; RERTKI/KI; Ink4a/Arf+/+ 
or Ink4a/Arf/. The mice were maintained on a mixed 129Sv/J/DBA/
C57BL/6 background. E4F1flox; RERT mice were genotyped by PCR on 
tail  genomic  DNA  using  the  following  primers.  (a)  E4F1 WT  (E4F1+) 
and conditional KO flox alleles (E4F1flox): 5-CCTTGAGCACGGAGGA-
GAGC-3 and 5-GCCCTAGCCTGCTCTGCCATC-3. (b) E4F1 con-
stitutive KO allele (E4F1): 5-CACTGCCTTGGAGGACTTTG-3 and 
5-CCTCTGTTCCACATACACTTCATTC-3. (c) WT and KI RERT al-
leles: 5-GTCAGTACACATACAGACTT-3, 5-TGAGCGAACAGGGC-
GAA-3,  and  5-TCCATGGAGCACCCAGTGAA-3.  (d)  Ink4a/Arf 
alleles: WT,  5-ATGATGATGGGCAACGTTC-3  and  5-CAAATATC-
GCACGATGTC-3; and KO, 5-CTATCAGGACATAGCGTTGG-3 and 
5-AGTGAGAGTTTGGGGACAGAG-3.
In vivo recombination of the E4F1flox allele was obtained by topical skin 
applications of 4OHT (Sigma-Aldrich) on shaved back skin of the trans-
planted recipient animals (2 mg/mouse/application; three applications). Cre-
mediated E4F1 recombination efficiency was assessed by immunoblotting or 
by qPCR analysis on genomic DNA using primers specific for the E4F1 locus, 
as described in Fig. S1 A: primer A, 5-GGCTGCTGCGTGGATTTC-3; B, 
5-GCTAGGTAGGGTAGGAGGCTGTCT-3;  C,  5-TTCGGTATAGT-
GTTGAGG-3; and D, 5-AGGGGCTGGGCTACAATGG-3.
For survival analyses, 4OHT administration started 10 wk after trans-
plantation and was repeated on a monthly basis throughout the entire life of 
the animals. For PET scan analyses, 4OHT (2 mg/mouse/application; three 
applications) was administrated around 20 wk after transplantation, when an-
imals exhibited obvious signs of tumor development. For NAC-based in vivo 
experiments, NAC was administrated at the final concentration of 40 mM in 
the drinking water (changed every day) for 7 d before 4OHT administration 
and maintained afterward during the total duration of the experiment (15 d). 
All animal husbandry and experiments were approved by and performed in 
accordance with the guidelines of the Institute of Molecular Genetics Ethics 
Committee (agreement no. B-34-172-16).
Transplantation experiments. Congenic C57BL/6-Ly5.1 mice were le-
thally irradiated (11 Gy) with a cobalt radiation source and used as recipient 
mice. 5 × 106 fetal liver donor HSCs isolated from Ly5.2 E4F1/flox or 
E4F1+/flox; RERTKI/KI; Ink4a/Arf+/+ or Ink4a/Arf/ embryonic day (E) 14.5 
embryos, were injected i.v. into the tail vain of recipient (Ly5.1) mice. Pe-
ripheral blood was obtained from retroorbital sinuses of recipient mice under 
isoflurane anesthesia and analyzed every 4 wk after transplantation by flow 
cytometry with several combinations of lineage-specific antibodies: APC-
CD19 for B cells, PerCP-CD3 for T cells, and APC-Gr1, FITC-F4/80, or JEM Vol. 208, No. 7 
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agar in 6-well plates in triplicate (100,000 cells per plate). Fresh medium, 
with or without 4OHT, was added every 3 d. Colonies were stained after   
3 wk of culture with a 0.5% crystal violet solution and counted.
Immunofluorescence  microscopy.  In  all  experiments,  HS  cells  were 
grown on a glass culture chamber (Falcon; BD). For LC3 immunostaining, 
cells were fixed with 2% paraformaldehyde for 5–10 min at room tempera-
ture, permeabilized by 0.1% Triton X-100 for 5 min at room temperature, 
incubated for 1 h with a blocking solution of PBS/1.5% BSA, and then 
stained for 1 h at 37°C with anti-LC3 antibody (Sigma-Aldrich) or over-
night at 4°C with anticatalase (Rockland), anti-HO1 (Stressgen), NQO1 
(Abcam), and anti-NRF2 (gift from E.E. Schmidt, Montana State University, 
Bozeman, MT) antibodies. After three washes in PBS/1% BSA/0.1% Tween 
20, the slides were incubated for 45 min at 37°C in the dark with FITC-
conjugated  anti–rabbit  secondary  antibody. To  visualize  oxidized  DNA   
(8-OHdG staining), cells were fixed with methanol at 20°C for 20 min and 
then incubated with 15 µg/ml FITC-conjugated avidin for 1 h at 37°C, as 
previously described (Radisky et al., 2005). To detect mitochondrial ROS, 
living cells were first incubated with MitoSOX (5 µM final) for 10 min at 
37°C and then fixed with 2% paraformaldehyde. Acidic vesicular organelles 
were visualized by staining cells with 1 µg/ml AO for 10 min at 37°C. All 
fixed cells were costained with DAPI for 5 min and mounted in Vectashield 
imaging medium (Vector Laboratories) before observation with an upright 
microscope (Axioimager Z1/apotome; Carl Zeiss). MitoSOX images were 
acquired with a gamma adjustment of 0.55.
Semiquantitative and quantitative immunoblotting. Total protein ex-
tracts were prepared by lysing HS cells or intraperitoneal primary macro-
phages in Triton X-100 lysis buffer (50 mM Tris-HCl, pH 7.4, 100 mM 
NaCl, 50 mM NaF, 5 mM EDTA, 40 mM -glycerophosphate, 1 mM Na 
orthovanadate, 104 M PMSF, 106 M leupeptin, 106 M pepstatin A, and 1% 
Triton X-100), separated by SDS-PAGE, and transferred to nitrocellulose 
membranes. Membranes were blocked in TBS containing 5% nonfat milk for 
1 h at room temperature and incubated overnight at 4°C with primary anti-
bodies. The following antibodies were used: E4F1 affinity-purified rabbit 
polyclonal antibody that was generated against the human full-length (aa 1–784) 
E4F1 protein, antiactin, and anti-LC3 antibodies (Sigma-Aldrich), anti-
GAPDH (Santa Cruz Biotechnology, Inc.), anti–phospho-Akt (S473) and 
anti–total Akt (Cell Signaling Technology), and anti-PTEN (A2B1; Santa 
Cruz Biotechnology, Inc.). Quantitative analyses with the infrared imaging 
system (Odyssey; LiCor) was performed using DyLight-conjugated secondary 
antibodies from Thermo Fisher Scientific. Semiquantitative enhanced chemi-
luminescence–based immunoblotting was performed using horseradish per-
oxidase–conjugated secondary antibodies purchased from GE healthcare.
Transmission electron microscopy and ultrastructural evaluation. 
Adherent HS cells were fixed in 3.5% glutaraldehyde in 0.1 M Sorensen’s 
phosphate buffer, pH 7.4, for 1 h at room temperature. The cells were then 
scrapped and maintained overnight at 4°C in this fixative solution. After 
washes in Sorensen’s buffer, cells were postfixed in a 1% osmic acid plus 0.8% 
potassium ferrocyanide for 2 h at room temperature in the dark. After two 
washes in Sorensen’s buffer, the cells were dehydrated in a graded series of 
ethanol solutions (30–100%) and embedded in EmBed 812 resin. Thin sec-
tions (85 nm) were cut on an ultramicrotome (Ultracut E; Leica) and col-
lected at different levels of each block. These sections were counterstained 
with uranyl acetate and examined on a transmission electron microscope 
(model 7100; Hitachi).
Lentiviral  particles  productions  and  infections. Viral particles were 
produced in HEK 293T cells by standard procedures after transfection of the 
following  constructs:  pLKO1  encoding  shRNAs  directed  against  human 
E4F1 (shE4F1#1, Sigma-Aldrich mission clone 1740s1c1; shE4F1#2, clone 
2411s1c1),  murine  p53  (sh  p53,  Sigma-Aldrich  mission  shRNA  clone 
1526s1c1), or an irrelevant shRNA (sh Ct, clone shc002). 48 h after transfec-
tion, viral particles were harvested in the supernatant and added overnight in 
HS cell lines and primary macrophages, the working concentrations of the   
following chemical reagents were used: 1 µg/ml AO, 1 mM 3MA, 3 µM 4OHT, 
100 µM Tiron, 200 µM NAC, and 10 µM D3T.
Viability, proliferation, cell death, and ROS detection assays.  Viability 
was determined by manual counting after trypan blue exclusion. The prolif-
eration rate of HS cells was assessed after incubation for 2 h with EdU by 
FACS analysis with the EdU flow cytometry assay kit (Invitrogen), according 
to the manufacturer’s recommendations. Mitotic cells were identified with 
the Ser10 phospho–histone H3 antibody (Cell Signaling Technology). Cell 
death was evaluated by flow cytometry upon annexin  V/PI staining. Total and 
mitochondrial ROS levels were evaluated by flow cytometry or immuno-
fluorescence microscopy, upon staining with CM-H2DFCDA, OxyBURST, 
and MitoSOX probes or the MitoSOX probe only, respectively, according to 
the manufacturer’s recommendations. As shown in Fig. 6 A (right), the kinet-
ics of MitoSOX staining were evaluated over a 75-min period. Quantitative 
data represent the fold increase of time-dependent changes in mean fluores-
cence intensity of MitoSOX staining measured by flow cytometry. Annexin 
V/PI and CM-H2DCFDA/MitoSOX analyses were performed on freshly 
trypsinized live cells on a flow cytometer (FACSCalibur; BD).
Isolation of HS cell lines and primary macrophages. Four HS cell 
lines (two E4F1+/flox and two E4F1/flox) were established ex vivo out of nine 
lungs and zero out of nine livers harvested from unrecombined E4F1 KO or 
CT; Ink4a/Arf KO animals, as follows: fresh HSs of appropriate genotype 
were harvested from transplanted recipient mice of 20 wk of age, mechani-
cally dissociated, digested in collagenase for 2 h at 37°C, and then cultured in 
RPMI Glutamax-I supplemented with 10% IFBS, 2.5 g/l glucose, 10 mM 
Hepes, and 1 mM Na pyruvate in a humidified 5% CO2, 37°C incubator. 
Primary macrophages were harvested by injection of 10 ml PBS in the intra-
peritoneal cavity of mice of appropriate genotype, centrifuged, and plated for 
2 h. Nonadherent cells were removed by repeated washing with culture me-
dium. Purity (>90%) of the adherent macrophage population was evaluated 
by flow cytometry with Mac2 antibody. Primary macrophages were cultured 
in the same conditions and medium than HS cells lines. E4F1 inactivation in 
HS cell lines and primary macrophages was obtained by the addition of 
4OHT to the culture medium, 2 h after plating.
Measurement of oxygen consumption and ATP production. Oxygen 
consumption  was  determined  by  two  independent  methods. The  XF24   
Extracellular Flux Analyzer (Seahorse Bioscience), based on fluorimetric sen-
sors, was used for real-time in situ measurement of the OCR in E4F1 HS 
cells and primary intraperitoneal macrophages. Analyses were conducted on 
80,000 cells/well in triplicate for each cell type (E4F1 CT or KO HS cells or 
primary macrophages). Mean values of OCRs were then calculated after cor-
rection to the total amount of cellular protein per well. For these experi-
ments, cells were incubated for 1 h at 37°C in HCO3-free DME containing 
25 mM glucose and 1 mM pyruvate. Measurement of OCR was performed 
over 2 min in three measurement intervals to assess basal metabolic rate, oli-
gomycin C (1 µg/ml final)–sensitive OCR associated to ATP production, and 
maximal respiratory capacity (upon FCCP [0.3 µM final] followed by rote-
none [0.1 µM final] administration). Oxygen consumption was also measured 
using a temperature-regulated Clark-type O2 electrode chamber (Strathkel-
vin Instruments) in murine E4F1 HS cells and human leukemic cell lines. 
Oxygen consumption was measured on 5 × 106 cells for 5–15 min (until   
oxygen consumption ceased) at 37°C in the presence of 2.5 mM malate and   
10 mM pyruvate, upon repeated ADP injection (three injections of ADP, 1 mM 
final). Respiration values were normalized to cell number. For ATP measure-
ments, 20,000 cells were plated in quadruplicates in a 96-well plate, and ATP 
was measured 3 h later by using the Cell Titer Glo (Promega) luminescent assay. 
In brief, cells were incubated in the lysis buffer, and the luminescence was   
determined 10 min later. ATP levels were normalized to total protein levels.
Soft agar assays. Single cell suspensions of HS cells were mixed with RPMI 
containing 0.4% noble agar and plated on the top of a layer containing 1% noble 1416 E4F1 drives survival of myeloid leukemic cells | Hatchi et al.
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the culture medium of E4F1 HS cells or U937, HEL, HL60, or THP1 human 
cell lines in the presence of polybrene (8 µg/ml final).
Human samples for E4F1 expression levels evaluation. Anonymous 
normal and AML BM samples were provided by the Laboratoire d’Hématologie, 
Hôpital St. Eloi, Centre Hospitalier Universitaire (collection no. DC-2010-
1185 approved by the French minister of health). Frozen vials were thawed 
in complete medium, and whole-cell extracts were prepared in Laemmli buf-
fer containing protease inhibitors. E4F1 and actin protein expression levels 
were determined by quantitative immunoblotting.
Statistic analyses. Unless otherwise indicated, the unpaired Student’s t test 
was used in all analyses, data in bar graphs are represented as mean ± SEM, 
and statistical significance was expressed as follows: *, P < 0.05; **, P < 0.01; 
***, P < 0.001.
Online supplemental material. Fig. S1 describes the HS mouse model 
used to decipher E4F1 functions during leukemic development. Fig. S2   
illustrates  tumor  regression  occurring  upon  E4F1  inactivation.  Fig.  S3 
shows deregulation of the PI3K pathway in HS cell lines. Fig. S4 shows the   
immunophenotypic characterization of HS cell lines. Fig. S5 shows the impact 
of caspase inhibitor and antioxidant molecules on cell death of E4F1 KO 
HS cells. Fig. S6 shows the induction of a cellular antioxidant response upon 
E4F1 inactivation in HS cells. Fig. S7 shows the role of p53 in cell death   
occurring in E4F1 KO HS cells. Fig. S8 shows the overexpression of E4F1 in 
murine HS cell lines and human AML samples. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20101995/DC1.
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